IP Library › Granted Patent US 12,221,468
Granted Patent B2
US 12,221,468 · App. 17/412,932 · Granted Feb 11, 2025

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

Inventors: Andrea Mahr (Tuebingen, DE); Toni Weinschenk (Tuebingen, DE); Anita Wiebe (Tuebingen, DE); Colette Song (Tuebingen, DE); Oliver Schoor (Tuebingen, DE); Jens Fritsche (Tuebingen, DE); Harpreet Singh (Tuebingen, DE)
Assignee: Immatics Biotechnologies GmbH
C07K14/70539A61K35/16A61K35/17A61K39/0011A61K39/39A61K39/4611A61K39/4644C07K14/4748C07K16/2833C07K16/3053C12N5/0636C12N5/0638A61K2039/55527A61K2039/55533A61K2039/572C07K7/00C07K16/18C12N15/115C12N2501/2312C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,468
App. No.
17/412,932
Granted
Feb 11, 2025
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (17)

1. An isolated peptide consisting of the amino acid sequence GLAGGFGGPGFPV (SEQ ID NO: 1) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I: C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

10. The composition of claim 7 , wherein the adjuvant is IL-12.

11. The composition of claim 7 , wherein the adjuvant is IL-15.

12. The composition of claim 7 , wherein the adjuvant is IL-21.

13. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

14. The composition of claim 7 , wherein the adjuvant is IL-1.

15. The composition of claim 7 , wherein the adjuvant is IL-4.

16. The composition of claim 7 , wherein the adjuvant is IL-13.

17. The composition of claim 7 , wherein the adjuvant is IL-23.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2021
From: MAHR, ANDREA; WEINSCHENK, TONI; WIEBE, ANITA; SONG, COLETTE; SCHOOR, OLIVER; FRITSCHE, JENS; SINGH, HARPREET
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 057300/0883 →
Priority Claims (1)
DE 10 2016 115 974.3 · Aug 26, 2016 · national
Continuity (9)
Continuation 17229682 · Apr 13, 2021
Continuation 17076261 · Oct 21, 2020
Continuation 16911028 · Jun 24, 2020
Continuation 16852189 · Apr 17, 2020
Continuation 16750908 · Jan 23, 2020
Continuation 16422335 · May 24, 2019
Continuation 15686679 · Aug 25, 2017
Provisional Application 62379864 · Aug 26, 2016
Related Publication 20210401888A1 · Dec 30, 2021
References Cited (55)
US 9132177B2 · Fritsche et al. · 2015 [cited by applicant]
US 10064924B2 · Rammensee et al. · 2018 [cited by applicant]
US 10071148B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10159725B2 · Fritsche et al. · 2018 [cited by applicant]
US 10286052B2 · Rammensee et al. · 2019 [cited by applicant]
US 10780125B2 · Mahr et al. · 2020 [cited by applicant]
US 10842817B2 · Mahr et al. · 2020 [cited by applicant]
US 11058726B2 · Mahr et al. · 2021 [cited by applicant]
US 11123370B2 · Mahr et al. · 2021 [cited by applicant]
US 11324812B2 · Mahr et al. · 2022 [cited by applicant]
US 20030119134A1 · Baker et al. · 2003 [cited by applicant]
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20100210829A1 · Linnemann et al. · 2010 [cited by applicant]
US 20110229524A1 · Fritsche et al. · 2011 [cited by applicant]
US 20130115188A1 · Fritsche et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20150320848A1 · Rammensee et al. · 2015 [cited by applicant]
US 20170319675A1 · Weinschenk et al. · 2017 [cited by applicant]
US 20180311330A1 · Rammensee et al. · 2018 [cited by applicant]
US 20200254022A1 · Mahr et al. · 2020 [cited by applicant]
US 20210252061A1 · Mahr et al. · 2021 [cited by applicant]
US 20220313805A1 · Mahr et al. · 2022 [cited by applicant]
US 20220323501A1 · Mahr et al. · 2022 [cited by applicant]
CL 2019000460A1 · 2019 [cited by applicant]
CL 2021000548A1 · 2021 [cited by applicant]
CL 2021000549A1 · 2021 [cited by applicant]
CL 2021000550A1 · 2021 [cited by applicant]
EP 1033401A2 · 2000 [cited by applicant]
WO 2003062391A2 · 2003 [cited by applicant]
WO 2008021290A2 · 2008 [cited by applicant]
WO 2011113872A1 · 2011 [cited by applicant]
WO 2012148720A2 · 2012 [cited by applicant]
WO 2013039477A1 · 2013 [cited by applicant]
WO 2014168242A1 · 2014 [cited by applicant]
WO 2015018805A1 · 2015 [cited by applicant]
WO 2015169945A2 · 2015 [cited by applicant]
WO 2015193359A2 · 2015 [cited by applicant]
WO 2016170139A1 · 2016 [cited by applicant]
WO 2017184590A1 · 2017 [cited by applicant]
Berge et al. (J. Pharm. Sci. Jan. 1977; 66 (1): 1-19). [cited by examiner]
Paulekuhn et al. (J. Med. Chem. Dec. 27, 2007; 50 (26): 6665-72). [cited by examiner]
Nakagawa et al. (Biophys J. Apr. 1, 2007; 92 (7): 2570-82). [cited by examiner]
He et al. (Life Sci. 1999; 65 (4): 355-68). [cited by examiner]
Ljunggren et al. (Nature. Aug. 2, 1990; 346 (6283): 476-80). [cited by examiner]
Bilich et al. (Blood. Feb. 7, 2019; 133 (6): 550-565). [cited by examiner]
Stevens et al. (Eur. J. Immunol. Apr. 1998; 28 (4): 1272-9). [cited by examiner]
Hervé et al. (Mol. Immunol. Feb. 1997; 34 (2): 157-63). [cited by examiner]
International Search Reporting for PCT/EP2017/071347 mailed Jan. 17, 2018. [cited by applicant]
“Human structural and cytoskeleton-associated protein (SCAP) #20.” Retrieved from EBI accession No. GSP: ADE15641. Jan. 29, 2004. [cited by applicant]
“Human keratin 6B protein, SEQ 4.” XP002774546, retrieved from EBI accession No. GSP:BBP53541. Dec. 4, 2014. [cited by applicant]
“Human keratin, type I cytoskeletal 17 (Cytokeratin 17) SEQ:114.” XP002774547, retrieved from EBI accession No. GSP:BAF31682. Dec. 20, 2012. [cited by applicant]
“Human cytokeratin 12 antigen.” XP002774548, retrieved from EBI accession No. GSP:BBC42354. Apr. 10, 2014. [cited by applicant]
B. Perez-Ordonez. “Molecular biology of squamous cell carcinoma of the head and neck.” Journal of Clinical Pathology. vol. 59(5): 445-453. Feb. 16, 2006. DOI: 10.1136/jcp.2003.007641. [cited by applicant]
Chang H et al. “A transcriptional network signature characterizes lung cancer subtypes”. Cancer. vol. 117, n2, pp. 353-360 (Jan. 15, 2011). [cited by applicant]
Nieves S et al. “Cytokeratins 14 and 19 in odontogenic cysts and tumors: a review”. Odontostomatology, vol. 16, N24. 2014 (English translation provided). [cited by applicant]